Our business model is to discover first-in-class, innovative therapeutics for the treatment of Rare and Ultra-Rare Diseases and license them to larger partners who will deliver them to market for the patients that need them.
Vision and Mission
Patient’s with Rare and Ultra-Rare diseases, and their families who care for and support them, face significant and numerous challenges in their daily lives.
Our focus is to use our innovative approach and expertise to discover new treatments, which these patients not only need but also clearly deserve, in order to improve their quality of life.
Atlas Molecular Pharma has a proprietary technological platform approach (CHASSYS™) which it plans to further develop and exploit to act as a “drug discovery engine” to deliver therapeutics (termed pharmacological chaperones) for the treatment of a range of Rare and Ultra-Rare Diseases.
By designing and discovering pharmacological chaperones (drugs) which associate to these enzymes and stabilise them, we will be able to resolve the corresponding pathology of the disease and have a significant positive impact on patient’s lives.
Research and Development
Óscar Millet, PhDChief Executive Officer
Óscar is currently Group Leader at the Structural Biology Unit of the CIC bioGUNE, has published 55 papers and has in-depth expertise in the use of nuclear magnetic resonance (NMR) for the study of biologically relevant proteins and enzymes and has been central to the development of technology for the discovery of pharmacological chaperones and the exploration of new therapeutic intervention lines against different Rare Diseases including Congenital Erythropoietic Porphyria (CEP).
Joaquín Castilla, PhDChief Scientific Officer
Joaquín obtained a Degree in Pharmacy (Univ. Navarra, 1992). After obtaining a PhD in Science (University Autónoma of Madrid, 1996) he performed post-doctoral research (1998-2003) first at Center for Animal Health (CISA -INIA) and then at Serono Pharmaceutical Institute in Switzerland. In 2004, he became Assistant Professor, first at the University of Texas, Medical Branch and later at Scripps (Florida) from 2006 leading an independent group. In 2009, he was then the recipient of an IKERBasque Research Professor and currently he is a Group Leader at the Proteomic Unit of the CIC bioGUNE (Center for Cooperative Research in Biosciences, Biscay, Spain).
Management and Advisory Team
José María Mato, PhDChairman
José María Mato is the founder and General Director of the Research Centers bioGUNE (Bilbao) and biomaGUNE (San Sebastián), and Research Professor of the Spanish National Research Council (CSIC), Spain. A graduate in Biochemistry at the University of Madrid, Professor Mato received a PhD degree from Leiden University and was awarded the CJ Kok prize for his thesis. He was a postdoctoral fellow at the Biozentrum of the University of Basel and the National Institutes of Health, and a faculty member at the Jiménez Díaz Foundation in Madrid before been named Research Professor at the CSIC. He has been Professor of the Faculty of Medicine of the University of Navarra and Visiting Professor at the University of Pennsylvania and Thomas Jefferson University. From 1992 to 1996 Professor Mato was President of the CSIC and in 2004 was awarded the Spanish National Research Prize in Medicine. He is the co-founder of OWL metabolomics in 2000 and of ATLAS Molecular Pharma in 2016.
Juan Manuel Falcón, PhDScientific Advisor
Juan obtained a Degree in Biology (Univ. Sevilla, 1994) and a PhD in Biological Sciences (“Alberto Sols” IIB-UAM, 1999) studying yeast as model for cystic fibrosis. He then occupied three postdoctoral positions; one in UAM (Madrid, 1999-2001) studying Walker-Warburg Syndrome, in UCLA (Los Angeles, 2001-2005) studying Hermansky-Pudlak syndrome, and through a Ramon y Cajal Program he incorporated into CIC bioGUNE (Bilbao). Since 2010, Juan has been an Ikerbasque Research Professor leading the exosomes laboratory and the metabolomics platform in CIC bioGUNE with research lines focused in on the discovery of low-invasive biomarkers and novel therapeutics tools for metabolic and rare- diseases.
Ganeko BernardoHead of project - Porphyria
Ganeko obtained a Degree in Biochemistry (University of Basque Country, 2011), a Master Degree in Molecular Biology and Biomedicine (University of Basque Country, 2012) and a PhD in Molecular Biology and Biomedicine (University of Basque Country, 2012). During his PhD he studied the calcium gating mechanism of a voltage-gated potassium channel based in NMR technique. In this period he got a Short-Term Fellowship in King’s College University (United Kingdom, 2015) where he gained expertise in Molecular Dynamic simulations and Bioinformatics. Since 2016 he is member of Atlas Molecular Pharma and he is involved in CHASSYS(TM) platform.
Hasier ErañaHead of project - Prion diseases
Hasier obtained a Degree in Biotechnology (Univ. Autònoma de Barcelona, 2010) and a Master’s degree in Microbiology (Univ. Autònoma de Barcelona, 2011) evaluating the use of Mycobacteria in the treatment of bladder cancer. He performed his PhD in Molecular Biology and Biomedicine (Univ. País Vasco, 2015) in CIC bioGUNE working on Transmissible spongiform encephalopaties focused on the interspecies transmission of these devastating neurodegenerative disorders. He has been working in the same institute as post-doctoral researcher during 2016.
Jorge MorenoHead of Project - Preclinical animal studies
Jorge Moreno Charco got his degree in Biology from the University of Salamanca in 2013 and obtained a Master’s degree in Neuroscience a year later at the “Instituto de Neurociencias de Castilla y León” (INCyL) working on the characterization of subtypes of GFAP in the optical nerve of zebrafish. Immediately he initiated his PhD at the Prion Research Laboratory from CIC bioGUNE under the supervision of Dr. Joaquín Castilla, where he developed a thesis focused on developing a high-throughput screening system for the detection of compounds that could inhibit prion propagation and thus, serve as a therapy for Transmissible Spongiform Encephalopathies. During this period, he acquired expertise on in vitro and in vivo modelling of prion disorders. After getting his PhD in Neurosciences from the University of the Basque Country (UPV/EHU) in 2018, he joined ATLAS Molecular Pharma as a postdoctoral researcher. During the last years, he has continued his work on the development of therapeutic strategies for prion diseases as responsible of most of the pharmacokinetics and pharmacodynamics studies in animal models as well as on in vitro prion propagation techniques based on recombinant prion protein.
María de los Reyes LuquePhD Student
María de los Reyes obtained a Degree in Biochemestry (University of Sevilla, 2018) and a Master’s degree in Medicines research, development, control and innovation (University of Granada, 2019). She is currently doing a PhD (Doctorado Industrial, BIKAINTEK) focused on the usement of ciclopirox and other pharmacological chaperones in porphyfyria cutanea tarda.